The Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab in combination for untreated, locally advanced or metastatic, triple negative breast cancer.
Please note that following on from advice received from the company the timelines for this appraisal have been revised.
We now anticipate that the appraisal will begin during late- May 2020 when we will write to you about how you can get involved.